Astallas和Sangamo治疗伙伴开发神经疾病的基因疗法。 Astellas and Sangamo Therapeutics partner to develop gene therapies for neurological diseases.

Astelllas和Sangamo治疗技术公司签订了一项许可证协议,为治疗神经疾病开发基因组药物。 Astellas and Sangamo Therapeutics have entered into a licensing agreement to develop genomic medicines for treating neurological diseases. 该协议的重点是使用卡比锡技术,这对于直接向大脑和神经系统提供基因疗法至关重要。 The agreement focuses on using capsid technology, which is crucial for delivering gene therapies directly to the brain and nervous system. 这项协作旨在为目前治疗选择有限的条件提供预先治疗。 This collaboration aims to advance treatments for conditions that currently have limited therapeutic options.